Spanish drugmaker Faes Farma has licensed the rights to sell its antihistamine bilastine in India to Merck Serono, the drugs unit of Germanyás Merck KGaA. India is Asiaás third largest pharmaceutical market, with a 10% growth rate and an emerging economy of 1.2 billion people. The drug for allergic rhinitis and chronic urticaria was filed for approval with European regulators on February 27, with Germany as the European Union reference member state. Faes has assigned rights to bilastine to privately-held Italian pharmaceutical company Menarini in 51 countries.